Stevanato Group strengthens in Asia with the opening of a new commercial office in Nagoya, Japan

The commercial hub will provide bulk and sterile glass primary packaging to the Japanese market further strengthening ties with local customers.

Stevanato Group, through Ompi, its specialist in glass primary packaging for the pharmaceutical industry, opens a commercial office in Nagoya, Japan, the third biggest pharmaceutical market in the world*. Being closer to Japanese customers that have already been served by Ompi in the past few years, the office will be able to offer an even wider product range and service level and accompany the growth of the market. The office will become operative starting from January 1st 2018.

Ompi will provide a wide range of glass primary packaging solutions ranging from bulk to EZ-fill® sterile solutions and analytical consultancy aimed at guaranteeing the integrity of parenteral medicines. The expansion in Asia strengthens the unique market positioning Ompi already enjoys in the sterile glass primary packaging market, after the launch of its RTU product portfolio in 2007.

With Ompi EZ-fill® process, containers are washed, sterilized and provided in trays or in nests and tubs ready to be used to the pharma companies, thus becoming the ideal solution either for small batches production, initially at the clinical trials stage, or for industrial production. Over the years, the technology has proven unique advantages in terms of an easy, flexible and streamlined process so pharmaceutical companies can ultimately reduce their total cost of ownership.

In addition to EZ-fill® process technology, thanks to its SG Lab, Stevanato Group offers laboratory analysis in terms of analytical chemistry, material properties and physical and mechanical performances to study the possible interactions between pharmaceutical products and containers.

"Ompi’s presence in Japan will be essential to respond to the highly demanding requirements of the Japanese pharmaceutical industry that has always been challenging glass primary packaging manufactures to provide innovative and high-quality containers.” says Andrea Zambon, Ompi of Japan President. “Ompi wants to be closer to its clients and to become the preferred partner for pharmaceutical companies not only for generic drugs – which the Japanese government is looking to increase – but also for biologic drugs that are likely to experience a fast growth over the next years.”

^*Source: IMS Health Data 2015

About Stevanato Group

Founded in 1949, the Stevanato Group is the world’s largest, privately owned designer and producer of glass parenteral packaging for the pharmaceutical industry.It comprises two operational divisions dedicated to serving the pharmaceutical industry. The Pharmaceutical Systems comprises Ompi, specializing in glass primary packaging, and Balda, focused on specialty plastics and delivery devices. The Engineering Systems comprises Spami, Optrel, InnoScan and SVM, specializing in glass processing, inspection systems, assembly and packaging solutions. These two divisions enjoy a close, synchronous relationship, featuring daily exchanges, which ensure that Stevanato Group has complete control over the entire production process. The Group also benefits from the SG Lab activity that provides technical and analytical services on the potential interaction between drug and container.

About Ompi

As part of the Pharmaceutical Systems division of Stevanato Group, Ompi offers the widest range of glass primary packaging, from the traditional ones, such as vials and ampoules, to the high-value ones such as syringes and cartridges for auto-injectors and pen-injectors. Vials, cartridges, and syringes are available, sterile and ready-to-fill (Ompi EZ-fill®). It is the world largest supplier of insulin cartridges.

Ompi boasts a global footprint with high-quality production plants in Europe (Piombino Dese and Latina in Italy, Bratislava in Slovakia), Mexico (Monterrey), China (Zhangjiagang, near Shanghai) and a brand new plant in Sete Lagoas, (Brazil).